<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993460</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #091145</org_study_id>
    <nct_id>NCT00993460</nct_id>
  </id_info>
  <brief_title>Study of Changes in Skeletal Muscle After Caloric Restriction</brief_title>
  <official_title>Diacylglycerols and Insulin Action in Skeletal Muscle Upon Caloric Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research has shown that fat stored within muscles affects the muscle's sensitivity to insulin&#xD;
      and ability to handle blood glucose. The purpose of this study is to examine the effects of&#xD;
      weight loss surgery-induced caloric restriction on the accumulation and types of fats within&#xD;
      skeletal muscle, as well as the effects of such caloric restriction on insulin sensitivity&#xD;
      and inflammatory responses in skeletal muscle. The investigator proposes that caloric&#xD;
      restriction will result in decreases in diacylglycerols enriched with saturated fat and&#xD;
      increases in diacylglycerols enriched with monounsaturated fats.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that in a setting of surgically-induced weight loss decrements in select DAGs&#xD;
      result in improved glucose utilization, altered insulin signaling and decreased inflammatory&#xD;
      responses. We propose to examine the impact of molecular DAG species accumulation on glucose&#xD;
      utilization, insulin signaling and inflammation in skeletal muscle from morbidly obese&#xD;
      subjects before/after 10% weight loss facilitated by Roux-en-Y Gastric Bypass (RYGB). We will&#xD;
      compare these results to those from a control, normal weight cohort&#xD;
&#xD;
      The detected differences in DAG molecular species, insulin action, inflammatory responses&#xD;
      between normal and obese subjects (before/after weight loss) will emphasize pathways&#xD;
      coordinately altered as a consequence of adiposity and RYGB surgery. The primary endpoints&#xD;
      for this study will be: Insulin sensitivity (glucose Rd, insulin levels, DAG mass, DAG&#xD;
      species amounts).Secondary endpoints will be: FFA levels, inflammatory cytokine production,&#xD;
      and insulin signaling in skeletal muscle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>UPLC-ESI MS/MS profiling of lipd extracts from muscle biopsies to evaluate effects of gastric bypass induced-caloric restriction on diacylglycerol molecular species accumulation.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of gastric bypass induced-caloric restriction on skeletal muscle insulin action via a hyperinsulinemic-euglycemic clamp and profiling markers of insulin signaling.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of gastric bypass induced-caloric restriction on lipid-mediated inflammatory responses by profiling cytokines and free fatty acids in blood and inflammation markers in skeletal muscle biopsies.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Normal body weight</arm_group_label>
    <description>Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y gastric bypass</arm_group_label>
    <description>Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, muscle tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female subjects approved for Roux-en-Y gastric bypass surgery at Vanderbilt University&#xD;
        Medical Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Normal Weight Subjects:&#xD;
&#xD;
               -  Age 21-65 years&#xD;
&#xD;
               -  BMI of 21 to 27 kg/m2&#xD;
&#xD;
               -  Normal glucose tolerance as determined by OGTT on day of screening&#xD;
&#xD;
               -  No family history of diabetes&#xD;
&#xD;
          -  For Morbidly Obese Subjects:&#xD;
&#xD;
               -  Age 21-65 years&#xD;
&#xD;
               -  BMI of 30 to 65 kg/m2&#xD;
&#xD;
               -  Scheduled for Roux-en-Y gastric bypass at Vanderbilt Medical Center&#xD;
&#xD;
               -  Insulin resistant as determined by OGTT on day of screening&#xD;
&#xD;
        Exclusion Criteria (for all subjects):&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Clinically significant hepatic or renal disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Any abnormality that would preclude safe completion of study&#xD;
&#xD;
          -  Use of statins&#xD;
&#xD;
          -  Use of thiazide or furosemide diuretics, beta blockers, or other chronic medications&#xD;
             with known adverse effects on glucose tolerance levels unless subject has been on&#xD;
             stable dose of such medications for the past 3 months before entering the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles R Flynn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naji Abumrad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Charles R. Flynn</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

